An evaluation of the efficacy of Repeton on proliferation of Peripheral Neuropathy.
An in-house study by The Gordon's Herbal Research Center (GHRC)

Experiments were performed in our research center to study the effects of Repeton on the containment of Peripheral Neuropathy. Repeton was administered orally through pill form to the sample group of patients.

Twenty data points for each treatment were collected and evaluated using statistical methods to compare the treatment progress.

Data indicates that Repeton is efficacious in the treatment of Peripheral Neuropathy. These preliminary laboratory studies and histological evaluation of patients treated with Repeton indicate that the compound inhibits the progress of the disease and further research should be conducted for confirmation.

Another controlled study to test the efficacy of Repeton for Peripheral Neuropathy.
Repeton has been developed for the treatment of Peripheral Neuropathy.

In a preliminary controlled study, Repeton has been administered orally in pill form in set group of patients.

Results were obtained for 200 patients . All had previous treatments of various natures.

The results from these treatments consisted of symptomatic relief.

None of the patients were receiving any oral or topical medications at the time of the Repeton treatment.

Treatment with Repeton was continued until two weeks in addition to the time of complete disappearance of symptoms.

The treatment periods ranged from four to twelve weeks.

Follow-ups after treatment ranged from seven months to three years and showed resolution of Peripheral Neuropathy with no clinical recurrences.

Here is a summary of the clinical trail conducted in compliance
with the protocol, cGCP, applicable regulatory requirements:

The extensive report includes over 300 pages and is 18 megabytes in size. The trials were a success.
The study concludes that 72 percent of patients experienced an improvement of 1 or more on the Physician’s Global Assessment (PGA).
53 percent of users saw a Physician’s Global Assessment (PGA) reduction of 2 or more.
17 percent saw a reduction of 3 or more.
67 percent of patients who started with a PGA of 4 (the most severe in the patient population) experienced an improvement of 2 or more.
89 percent of patients who started with a PGA of 4 (the most severe) experienced an improvement of 1 or more on a scale of 5 in the PGA.
91 percent of the patents started the study with a condition classified as “deteriorating.”
100 percent of the patients tested experienced no side effects while using Repeton.
Based on this data it is believed that if the medication protocol treatment period was longer, the results would have been even better.
The clinical trials on Repeton were conducted under the regulations of FDA and New Zealand health authority.